Print
Email
ACADIA Pharmaceuticals Inc. (ACAD) filed Quarterly Report for the period ended 2011-09-30.
Acadia Pharmaceuticals Inc. has a market cap of $62.8 million; its shares were traded at around $1.19 with a P/E ratio of 2.9 and P/S ratio of 1.5.
This is the annual revenues and earnings per share of ACAD over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of ACAD.
Highlight of Business Operations:
Revenues decreased to $584,000 for the three months ended September 30, 2011 from $2.3 million for the three months ended September 30, 2010. This decrease was primarily due to the conclusion of our collaboration with Biovail in October 2010, at which time we recognized all remaining revenues related to that collaboration. We recognized $1.7 millionin revenues from that collaboration during the three months ended September 30, 2010. Revenues from our collaborations with Allergan totaled $278,000 for the three months ended September 30, 2011 and were comparable to the revenues from these collaborations for the three months ended September 30, 2010. Revenues from our agreements with other parties, including our collaboration with Meiji Seika Pharma, totaled $306,000 for the three months ended September 30, 2011 compared to $372,000 for the three months ended September 30, 2010.
Revenues decreased to $1.5 million for the nine months ended September 30, 2011 from $6.7 million for the nine months ended September 30, 2010. This decrease was primarily due to the conclusion of our collaboration with Biovail in October 2010, at which time we recognized all remaining revenues related to that collaboration. We recognized $4.9 million in revenues from that collaboration during the nine months ended September 30, 2010. Revenues from our collaborations with Allergan totaled $814,000 for the nine months ended September 30, 2011 and were comparable to the revenues from these collaborations for the nine months ended September 30, 2010. Revenues from our agreements with other parties, including our collaboration with Meiji Seika Pharma, totaled $665,000 for the nine months ended September 30, 2011 compared to $1.0 million for the nine months ended September 30, 2010.
Subscribe RSS
